Re: Value

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Value

in response to

Re: Value

Hartland

posted on Aug 23, 2017 04:37PM

Hartland,

As far as I know, nothing new has been disclosed about the two ongoing ZEN-3694 trials since I summarized in this post from mid-July, which included info from their last update (slides only) at BIO International. No webcasts in 2017. The single agent ZEN-3694 trial apparently is ongoing but no longer recruiting according to ClinicalTrials.gov (see this post). Seems that Zenith hired Dr. Edward van der Horst as Vice President, Discovery Biology & Pre-Clinical Development in late July (as originally posted by frohlir944) Only event listed on their website event page is BIO Investor Forum 2017, San Francisco, CA, October 17-18, 2017.